{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:39:34Z","timestamp":1790131174549,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112582","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:49:54Z","timestamp":1720428594000},"page":"112582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC"],"prefix":"10.1016","volume":"138","author":[{"given":"Lili","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-7615","authenticated-orcid":false,"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112582_b0005","doi-asserted-by":"crossref","unstructured":"N. Patsoukis, J.S. Duke-Cohan, A. Chaudhri, et al., Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation[Z]. 3 (2020) 128.","DOI":"10.1038\/s42003-020-0845-0"},{"key":"10.1016\/j.intimp.2024.112582_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling cancer and beyond[J]","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy[J]","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112582_b0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab a bispecific B-cell and T-cell engaging antibody in the treatment of B-cell malignancies[J]","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.112582_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090884","article-title":"Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies[J]","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.intimp.2024.112582_b0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges[J]","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6545","key":"10.1016\/j.intimp.2024.112582_b0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies[J]","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2024.112582_b0045","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells[J]","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.intimp.2024.112582_b0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab an anti-PD-1\/CTLA-4 bispecific antibody for patients with advanced solid tumours (COMPASSION-03): a multicentre open-label phase 1b\/2 trial[J]","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112582_b0055","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval[J]","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.intimp.2024.112582_b0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline[J]","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2024.112582_b0065","article-title":"Clinical cancer immunotherapy: Current progress and prospects[J]","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors[J]","volume":"10","author":"Wu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112582_b0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery[J]","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions[J]","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.intimp.2024.112582_b0085","doi-asserted-by":"crossref","first-page":"e2202977","DOI":"10.1002\/adhm.202202977","article-title":"A Bispecific peptide-polymer conjugate bridging target-effector cells to enhance Immunotherapy[J]","volume":"12","author":"Zhang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"16","key":"10.1016\/j.intimp.2024.112582_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612931","article-title":"Peptide-based agents for cancer treatment: current applications and future directions[J]","volume":"24","author":"Nhan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112582_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119984","article-title":"Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression[J]","volume":"247","author":"Gurung","year":"2020","journal-title":"Biomaterials"},{"issue":"44","key":"10.1016\/j.intimp.2024.112582_b0100","doi-asserted-by":"crossref","first-page":"18536","DOI":"10.1021\/jacs.1c08132","article-title":"Rational design of potent peptide Inhibitors of the PD-1:PD-L1 Interaction for cancer immunotherapy[J]","volume":"143","author":"Yin","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.intimp.2024.112582_b0105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4143\/crt.2021.424","article-title":"Engineering a high-affinity pd-1 peptide for optimized immune cell-mediated tumor therapy[J]","volume":"54","author":"Chen","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"17","key":"10.1016\/j.intimp.2024.112582_b0110","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval[J]","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.112582_b0115","doi-asserted-by":"crossref","first-page":"14369","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab[J]","volume":"8","author":"Tan","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cr.2016.77","article-title":"Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab[J]","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res."},{"issue":"26","key":"10.1016\/j.intimp.2024.112582_b0125","doi-asserted-by":"crossref","first-page":"14944","DOI":"10.1039\/C9RA01369E","article-title":"Computational analysis of hot spots and binding mechanism in the PD-1\/PD-L1 interaction[J]","volume":"9","author":"Huang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.intimp.2024.112582_b0130","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials[J]","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112582_b0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/19420862.2018.1518948","article-title":"Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1\/PD-1 targeted immunotherapy[J]","volume":"10","author":"Lin","year":"2018","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.intimp.2024.112582_b0140","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.celrep.2019.07.059","article-title":"Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T Cell-Mediated Immunity in pancreatic ductal adenocarcinoma[J]","volume":"28","author":"Burrack","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2024.112582_b0145","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw378.05","article-title":"Combination of MEDI0680 an anti- with durvalumab an anti-PD-L1 antibody: A phase 1 open-label study in advanced malignancies[J]","volume":"27","author":"Hamid","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10272","key":"10.1016\/j.intimp.2024.112582_b0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre randomised open-label phase 3 trial[J]","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112582_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy[J]","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"6","key":"10.1016\/j.intimp.2024.112582_b0160","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I Trial of M7824 (MSB0011359C) a bifunctional fusion protein targeting PD-L1 and TGFbeta in advanced solid tumors[J]","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112582_b0165","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo[J]","volume":"194","author":"Das","year":"2015","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112582_b0170","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2326-6066.CIR-20-0304","article-title":"Bispecific targeting of PD-1 and PD-L1 enhances T-cell activation and antitumor immunity[J]","volume":"8","author":"Kotanides","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"7718","key":"10.1016\/j.intimp.2024.112582_b0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T01:47:24Z","timestamp":1728352044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924011032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"alternative-id":["S1567576924011032"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112582","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112582"}}